Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2006
gptkb:European_Union gptkb:United_States |
| gptkbp:can_be_combined_with |
gptkb:ritonavir
|
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:contraindication |
severe liver disease
|
| gptkbp:developed_by |
gptkb:Tibotec_Pharmaceuticals
|
| gptkbp:dosage_form |
600 mg tablet
|
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
fixed-dose combination
|
| https://www.w3.org/2000/01/rdf-schema#label |
TMC114
|
| gptkbp:indication |
treatment-naive patients
treatment-experienced patients |
| gptkbp:interacts_with |
gptkb:St._John's_Wort
gptkb:carbamazepine gptkb:rifampin |
| gptkbp:invention |
gptkb:Johnson_&_Johnson
|
| gptkbp:is_a_guide_for |
WHO guidelines
CDC guidelines |
| gptkbp:known_as |
gptkb:Darunavir
|
| gptkbp:lifespan |
8 to 15 hours
|
| gptkbp:marketed_as |
gptkb:Prezista
|
| gptkbp:mechanism_of_action |
protease inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
high bioavailability
|
| gptkbp:provides_guidance_on |
gptkb:HAART
|
| gptkbp:research_focus |
pharmacogenomics
drug-drug interactions cost-effectiveness analysis patient-reported outcomes quality of life improvements healthcare access issues drug resistance treatment optimization pediatric use long-term efficacy real-world effectiveness adherence strategies co-infection management community engagement in treatment long-term side effects safety in pregnancy stigma reduction strategies treatment discontinuation effects |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
headache
nausea diarrhea rash |
| gptkbp:target_audience |
HIV-positive patients
|
| gptkbp:used_for |
treatment of HIV
|
| gptkbp:bfsParent |
gptkb:Tibotec
|
| gptkbp:bfsLayer |
5
|